| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 7 | 2024 | 133 | 4.310 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2024 | 798 | 3.410 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2024 | 399 | 2.230 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2024 | 889 | 2.090 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2024 | 359 | 2.030 |
Why?
|
| Sulfonamides | 4 | 2024 | 318 | 1.630 |
Why?
|
| Aminopyridines | 2 | 2023 | 40 | 1.570 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2023 | 23 | 1.550 |
Why?
|
| Triazines | 2 | 2023 | 54 | 1.550 |
Why?
|
| Disease Management | 6 | 2024 | 326 | 1.440 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2024 | 91 | 1.160 |
Why?
|
| Anemia | 2 | 2024 | 132 | 1.070 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 2328 | 0.980 |
Why?
|
| CD47 Antigen | 1 | 2024 | 23 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 2505 | 0.900 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2023 | 55 | 0.890 |
Why?
|
| Aniline Compounds | 1 | 2023 | 59 | 0.880 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 54 | 0.870 |
Why?
|
| Pyrazines | 1 | 2023 | 91 | 0.860 |
Why?
|
| Air Pollutants | 1 | 2024 | 96 | 0.850 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 107 | 0.770 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2021 | 16 | 0.750 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2021 | 21 | 0.740 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 13 | 0.740 |
Why?
|
| Mutation | 10 | 2024 | 4164 | 0.730 |
Why?
|
| Humans | 55 | 2024 | 89768 | 0.730 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 187 | 0.720 |
Why?
|
| Disease Susceptibility | 4 | 2024 | 200 | 0.710 |
Why?
|
| Pyrrolidines | 1 | 2020 | 60 | 0.710 |
Why?
|
| Benzamides | 1 | 2020 | 234 | 0.680 |
Why?
|
| Lymphoma, Follicular | 1 | 2020 | 73 | 0.670 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 112 | 0.660 |
Why?
|
| Blast Crisis | 3 | 2024 | 37 | 0.660 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 260 | 0.640 |
Why?
|
| Pyrimidines | 1 | 2020 | 370 | 0.600 |
Why?
|
| Treatment Outcome | 10 | 2024 | 8240 | 0.590 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2024 | 412 | 0.560 |
Why?
|
| Middle Aged | 19 | 2024 | 26076 | 0.500 |
Why?
|
| Primary Myelofibrosis | 2 | 2024 | 67 | 0.460 |
Why?
|
| Male | 19 | 2024 | 42578 | 0.420 |
Why?
|
| Antibodies, Bispecific | 3 | 2021 | 28 | 0.410 |
Why?
|
| Azacitidine | 2 | 2024 | 147 | 0.400 |
Why?
|
| Aged | 16 | 2024 | 19209 | 0.390 |
Why?
|
| Retreatment | 2 | 2022 | 107 | 0.380 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 586 | 0.380 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 6777 | 0.370 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 605 | 0.370 |
Why?
|
| Enzyme Inhibitors | 2 | 2023 | 644 | 0.350 |
Why?
|
| Adult | 16 | 2024 | 26762 | 0.340 |
Why?
|
| Female | 16 | 2024 | 46491 | 0.320 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 2367 | 0.300 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 280 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1350 | 0.290 |
Why?
|
| Hemoglobins | 2 | 2024 | 193 | 0.270 |
Why?
|
| Remission Induction | 3 | 2024 | 740 | 0.270 |
Why?
|
| Disease Progression | 2 | 2020 | 1466 | 0.270 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 130 | 0.260 |
Why?
|
| Philadelphia Chromosome | 2 | 2024 | 42 | 0.260 |
Why?
|
| Prospective Studies | 3 | 2024 | 4320 | 0.260 |
Why?
|
| Risk Factors | 4 | 2024 | 5538 | 0.260 |
Why?
|
| Young Adult | 9 | 2024 | 6386 | 0.260 |
Why?
|
| Mastocytosis, Systemic | 1 | 2024 | 12 | 0.240 |
Why?
|
| Prognosis | 5 | 2024 | 3785 | 0.230 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.220 |
Why?
|
| Hepatitis B | 1 | 2024 | 76 | 0.220 |
Why?
|
| Air Pollution | 1 | 2024 | 93 | 0.210 |
Why?
|
| Janus Kinase 2 | 1 | 2023 | 60 | 0.210 |
Why?
|
| Adolescent | 7 | 2024 | 9325 | 0.200 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1607 | 0.200 |
Why?
|
| Cytogenetics | 1 | 2021 | 27 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 268 | 0.200 |
Why?
|
| Leukemia | 1 | 2024 | 322 | 0.190 |
Why?
|
| Immunocompetence | 1 | 2021 | 26 | 0.190 |
Why?
|
| Castleman Disease | 1 | 2021 | 14 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2021 | 109 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 594 | 0.190 |
Why?
|
| Uridine | 1 | 2021 | 56 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 2360 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 46 | 0.190 |
Why?
|
| Janus Kinases | 1 | 2020 | 23 | 0.180 |
Why?
|
| Clonal Evolution | 1 | 2020 | 16 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 58 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 265 | 0.180 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 358 | 0.180 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 84 | 0.180 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 386 | 0.170 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 114 | 0.170 |
Why?
|
| Retrospective Studies | 9 | 2024 | 9156 | 0.170 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 54 | 0.170 |
Why?
|
| Feedback | 1 | 2020 | 134 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 599 | 0.170 |
Why?
|
| Drug Resistance | 1 | 2020 | 232 | 0.170 |
Why?
|
| Uncertainty | 1 | 2019 | 76 | 0.160 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 401 | 0.160 |
Why?
|
| Patient Care | 1 | 2020 | 102 | 0.160 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2018 | 16 | 0.160 |
Why?
|
| Exercise | 1 | 2022 | 326 | 0.160 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 374 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 279 | 0.160 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 52 | 0.150 |
Why?
|
| Environment | 1 | 2020 | 225 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 203 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 264 | 0.150 |
Why?
|
| Genomics | 2 | 2020 | 776 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 431 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 449 | 0.150 |
Why?
|
| Neoplasms | 2 | 2023 | 3062 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2019 | 284 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 384 | 0.140 |
Why?
|
| Recurrence | 1 | 2020 | 1143 | 0.140 |
Why?
|
| Blood Pressure | 1 | 2021 | 902 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2019 | 344 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1704 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 476 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 476 | 0.130 |
Why?
|
| Internal Medicine | 1 | 2019 | 362 | 0.130 |
Why?
|
| Age Factors | 1 | 2020 | 1879 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1134 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1542 | 0.120 |
Why?
|
| HIV Infections | 1 | 2024 | 847 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 2000 | 0.120 |
Why?
|
| Biomarkers | 1 | 2020 | 1772 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2020 | 1062 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2023 | 3402 | 0.110 |
Why?
|
| Sweet Syndrome | 1 | 2013 | 5 | 0.110 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2012 | 3 | 0.100 |
Why?
|
| Histone Deacetylase 2 | 1 | 2012 | 8 | 0.100 |
Why?
|
| Allografts | 2 | 2024 | 184 | 0.100 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2012 | 154 | 0.100 |
Why?
|
| Transplantation, Homologous | 2 | 2024 | 995 | 0.090 |
Why?
|
| Histones | 1 | 2012 | 333 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 344 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 559 | 0.080 |
Why?
|
| Animals | 3 | 2023 | 27511 | 0.070 |
Why?
|
| Fever | 2 | 2021 | 127 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 740 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2022 | 794 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2583 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 122 | 0.060 |
Why?
|
| Blood Substitutes | 1 | 2024 | 8 | 0.060 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2024 | 14 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2012 | 1665 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.060 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 4 | 0.060 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.060 |
Why?
|
| Consolidation Chemotherapy | 1 | 2024 | 23 | 0.060 |
Why?
|
| Bilirubin | 1 | 2024 | 131 | 0.060 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 32 | 0.060 |
Why?
|
| Europe | 1 | 2024 | 324 | 0.060 |
Why?
|
| Milk | 1 | 2023 | 53 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 68 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2024 | 171 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2023 | 53 | 0.060 |
Why?
|
| Sheep | 1 | 2023 | 251 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 37 | 0.060 |
Why?
|
| Induction Chemotherapy | 1 | 2024 | 152 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 2024 | 73 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 108 | 0.050 |
Why?
|
| Cytarabine | 1 | 2024 | 219 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 233 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 378 | 0.050 |
Why?
|
| Isoantibodies | 1 | 2024 | 120 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 277 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 103 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 181 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 194 | 0.050 |
Why?
|
| Acute Disease | 1 | 2024 | 844 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 230 | 0.050 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 20 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 727 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 373 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 97 | 0.040 |
Why?
|
| Fatigue | 1 | 2021 | 173 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 1890 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2024 | 384 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2020 | 116 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2024 | 664 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 147 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2022 | 191 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 234 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 233 | 0.040 |
Why?
|
| United States | 2 | 2024 | 7080 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 116 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 278 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 865 | 0.040 |
Why?
|
| Burnout, Professional | 1 | 2020 | 102 | 0.040 |
Why?
|
| Boron Compounds | 1 | 2018 | 20 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 77 | 0.040 |
Why?
|
| Glycine | 1 | 2018 | 95 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 278 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 247 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1496 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 11846 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 316 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 2314 | 0.030 |
Why?
|
| Apoptosis | 1 | 2023 | 1717 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 484 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 539 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 602 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1431 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2886 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 2450 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2013 | 16 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1283 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2012 | 4 | 0.030 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2012 | 11 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2012 | 25 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 107 | 0.030 |
Why?
|
| Physicians | 1 | 2019 | 691 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 86 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2012 | 123 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2012 | 70 | 0.020 |
Why?
|
| Neutrophils | 1 | 2013 | 311 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2674 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 740 | 0.020 |
Why?
|
| Chromatin | 1 | 2012 | 403 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 423 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 961 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1491 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1158 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1244 | 0.020 |
Why?
|